Information Provided By: 
Fly News Breaks for January 7, 2016
DVAX
Jan 7, 2016 | 11:05 EDT
William Blair analyst Y. Katherine Xu noted that Dynavax's Phase III study of Heplisav met both its co-primary endpoints, prompting her to raise her probability of commercialization to 90% from 85%. The analyst, who continues to expect Heplisav to launch in the U.S. in the third quarter of this year, raised her price target on Dynavax shares to $45 from $42.
News For DVAX From the Last 2 Days
There are no results for your query DVAX
